Satoshi Otsu
Yufu, 8795593, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
T-cell invigoration to cell-free DNA ratio associated with anti-PD-1 response in gastric or gastro-esophageal junction adenocarcinoma: VOYAGER trial.
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2).
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid (NAPOLEON-2 study).
Journal: Therapeutic advances in medical oncology
Published: October 31, 2025
Relationship between immune-related adverse events and treatment outcome of immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective cohort study.
Journal: Journal of thoracic disease
Published: September 26, 2025
Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of data from the multicenter NAPOLEON-2 study.
Journal: Therapeutic advances in medical oncology
Published: June 26, 2025
Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.
Journal: International journal of clinical oncology
Published: June 24, 2025
Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer.
Journal: Frontiers in oncology
Published: May 11, 2025
Chemotherapy-induced neutropenia predicts short-term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid.
Journal: International journal of cancer
Published: April 06, 2025
Impact of Cancer Cachexia Progression on OATP1B1 Transport Activity: Quantitative Analysis Using Coproporphyrin-I as an Endogenous Biomarker.
Journal: Clinical pharmacology and therapeutics
Published: December 18, 2024
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302).
Journal: Therapeutic advances in medical oncology
Published: November 21, 2024
Last Updated: 09/26/2026